These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 19413658)

  • 1. Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate.
    Oizumi T; Yamaguchi K; Funayama H; Kuroishi T; Kawamura H; Sugawara S; Endo Y
    Basic Clin Pharmacol Toxicol; 2009 May; 104(5):384-92. PubMed ID: 19413658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
    Oizumi T; Funayama H; Yamaguchi K; Yokoyama M; Takahashi H; Yamamoto M; Kuroishi T; Kumamoto H; Sasaki K; Kawamura H; Sugawara S; Endo Y
    J Oral Maxillofac Surg; 2010 May; 68(5):1043-54. PubMed ID: 20156665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of anti-resorptive effects on bone.
    Kim S; Seiryu M; Okada S; Kuroishi T; Takano-Yamamoto T; Sugawara S; Endo Y
    Eur J Pharmacol; 2013 Jan; 699(1-3):14-22. PubMed ID: 23201069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNFalpha, macrophages, and T-cells.
    Deng X; Yu Z; Funayama H; Yamaguchi K; Sasano T; Sugawara S; Endo Y
    Int Immunopharmacol; 2007 Feb; 7(2):152-61. PubMed ID: 17178381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-IL-1β accumulation in macrophages by alendronate and its prevention by clodronate.
    Shikama Y; Nagai Y; Okada S; Oizumi T; Shimauchi H; Sugawara S; Endo Y
    Toxicol Lett; 2010 Nov; 199(2):123-8. PubMed ID: 20804833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate.
    Deng X; Yu Z; Funayama H; Shoji N; Sasano T; Iwakura Y; Sugawara S; Endo Y
    Toxicol Appl Pharmacol; 2006 May; 213(1):64-73. PubMed ID: 16203021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate augments interleukin-1beta release from macrophages infected with periodontal pathogenic bacteria through activation of caspase-1.
    Deng X; Tamai R; Endo Y; Kiyoura Y
    Toxicol Appl Pharmacol; 2009 Feb; 235(1):97-104. PubMed ID: 19063908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates].
    Endo Y; Funayama H; Yamaguchi K; Monma Y; Yu Z; Deng X; Oizumi T; Shikama Y; Tanaka Y; Okada S; Kim S; Kiyama T; Bando K; Shima K; Suzuki H; Takahashi T
    Yakugaku Zasshi; 2020; 140(1):63-79. PubMed ID: 31902887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice.
    Okada S; Kiyama T; Sato E; Tanaka Y; Oizumi T; Kuroishi T; Takahashi T; Sasaki K; Sugawara S; Endo Y
    Tohoku J Exp Med; 2013 Oct; 231(2):145-58. PubMed ID: 24140868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphonocarboxylates Can Protect Mice against the Inflammatory and Necrotic Side Effects of Nitrogen-Containing Bisphosphonates by Inhibiting Their Entry into Cells via Phosphate Transporters.
    Kiyama T; Tsuchiya M; Okada S; Oizumi T; Yamaguchi K; Sasaki K; Sugawara S; Endo Y
    Biol Pharm Bull; 2016; 39(5):712-20. PubMed ID: 27150143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model.
    Yu Z; Funayama H; Deng X; Kuroishi T; Sasano T; Sugawara S; Endo Y
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):222-9. PubMed ID: 16176557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and bisphosphonate induced osteonecrosis.
    Sawatari Y; Marx RE
    Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):487-98, v-vi. PubMed ID: 18088900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).
    Endo Y; Kumamoto H; Nakamura M; Sugawara S; Takano-Yamamoto T; Sasaki K; Takahashi T
    Biol Pharm Bull; 2017; 40(6):739-750. PubMed ID: 28566618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate.
    Funayama H; Ohsako M; Monma Y; Mayanagi H; Sugawara S; Endo Y
    Calcif Tissue Int; 2005 Jun; 76(6):448-57. PubMed ID: 15895282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release of Nitrogen-Containing Bisphosphonates (NBPs) from Hydroxyapatite by Non-NBPs and by Pyrophosphate.
    Bando K; Oizumi T; Takahashi T; Mizoguchi I; Sugawara S; Endo Y
    Biol Pharm Bull; 2021; 44(11):1670-1680. PubMed ID: 34719644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating low- and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases.
    Alons K; Kuijpers SC; de Jong E; van Merkesteyn JP
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Feb; 107(2):e1-7. PubMed ID: 19071040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
    Diel IJ; Fogelman I; Al-Nawas B; Hoffmeister B; Migliorati C; Gligorov J; Väänänen K; Pylkkänen L; Pecherstorfer M; Aapro MS
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):198-207. PubMed ID: 17855108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
    Otto S; Pautke C; Opelz C; Westphal I; Drosse I; Schwager J; Bauss F; Ehrenfeld M; Schieker M
    J Oral Maxillofac Surg; 2010 Nov; 68(11):2837-45. PubMed ID: 20971371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.